Treatment of peripheral vascular disease with misoprostol
(Cytotec(R)): A pilot study

Goszcz, A; Grodzínska, L; Kostka-Trabka, E; Bieroń, K; Sławiński, M; Jachym, R; Ochmański, W

doi:10.1358/mf.1998.20.5.485706

Cited by 7 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even in nonpregnant women, prostaglandin E 1 suppresses the action and secretion of vasopressin during radical hysterectomy 13 . A pilot study of patients with peripheral vascular disease noted that the therapeutic use of misoprostol could increase blood flow 14 …”

Section: Discussionmentioning

confidence: 99%

Can misoprostol reduce blood loss in laparoscopy-assisted vaginal hysterectomy?

Park¹,

Yoon²,

Seong³

et al. 2011

Australian and New Zealand Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Can misoprostol reduce blood loss in laparoscopy-assisted vaginal hysterectomy?

Park¹,

Yoon²,

Seong³

et al. 2011

Australian and New Zealand Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

show abstract

“…In a pilot trial, misoprostol significantly improved pain-free walking distance and ankle-brachial indexes [84].…”

Section: Pharmacologic Therapymentioning

confidence: 92%

Treatment of Chronic Peripheral Arterial Disease

2003

CVP

View full text Add to dashboard Cite

Peripheral arterial disease (PAD) is a common but under-recognized problem. Intermittent claudication is the most frequent symptom of PAD, although the diagnosis of PAD is often overlooked until the patient is presented with limb-threatening ischemia. Importantly, PAD is a marker of generalized atherosclerosis and is closely associated with coronary and cerebrovascular disease. The primary causes of death in patients with PAD are myocardial infarction and stroke. Reducing risk factors is an integral and aggressive part of the treatment regimen. The recognition and diagnosis of PAD, combined with its appropriate medical management, may well reduce the overall risk of cardiovascular morbidity. When diagnosed early, both exercise and pharmacotherapy can ameliorate symptoms of claudication. augment functional performance, and improve quality of life. This review focuses on the general medical management and specific therapeutic options. Because PAD is a manifestation of generalized atherosclerosis, the principal issue in medical management of PAD is a treatment plan that modifies known risk factors for atherosclerosis and its atherothrombotic complications. All patients with PAD should be receiving antiplatelet therapy to prevent ischemic events and ACE inhibitors should be used if appropriate. Medical treatment for patients with claudication includes exercise in rehabilitation and drug therapy. It is also recognized that selected patients with claudication symptoms may benefit from catheter-based interventions, and most PAD patients with critical leg ischemia require revascularization procedures. Although many therapies for claudication have been thoroughly investigated, research continues on new treatments. In contrast, more prospective, randomized trials are needed to evaluate various therapies for treating patients with PAD.

show abstract

“…In addition, the ankle:arm ratio and arterial blood pressure increased in both limbs during treatment. 44,45 Topical administration of misoprostol was effective against periodontal disease and oral ulcers caused by radiation therapy and chemotherapy, and this product is patented. 46 Several preclinical studies suggest that surgical implantation of a PGE 1 analogmethacrylate composite can promote guided tissue regeneration and periodontal repair and healing in dogs.…”

Section: Novel Pharmacologic Effectsmentioning

confidence: 99%

Misoprostol Therapeutics Revisited

2001

View full text Add to dashboard Cite

Misoprostol, a prostaglandin E1 analog, is a racemate of four stereoisomers. On administration it rapidly de-esterifies to its active form, misoprostolic acid. Misoprostolic acid is 85% albumin bound and has a half-life of approximately 30 minutes. It is excreted in urine as inactive metabolites. No significant drug interactions have been reported. Besides its gastrointestinal protective and uterotonic activities, misoprostol regulates various immunologic cascades. It inhibits platelet-activating factor and leukocyte adherence, and modulates adhesion molecule expression. It protects against gut irradiation injury, experimental gastric cancer, enteropathy, and constipation. It improves nutrient absorption in cystic fibrosis. Misoprostol has utility in acetaminophen and ethanol hepatotoxicity, hepatitis, and fibrosis. It is effective in asthmatics and aspirin-sensitive asthmatic and allergic patients. It lowers cholesterol and severity of peripheral vascular diseases, prolongs survival of cardiac and kidney transplantation, synergizes cyclosporine, and protects against cyclosporine-induced renal damage. It works against drug-induced renal damage, interstitial cystitis, lupus nephritis, and hepatorenal syndrome. It is useful in periodontal disease and dental repair. Misoprostol enhances glycosoaminoglycan synthesis in cartilage after injury. It prevents ultraviolet-induced cataracts and reduces intraocular pressure in glaucoma and ocular hypertension. It synergizes antiinflammatory and analgesic effects of diclofenac or colchicine and has been administered to treat trigeminal neuralgic pain. It reduces chemotherapy-induced hair loss and recovery time from burn injury, and is effective in treating sepsis, multiple sclerosis, and pancreatitis.

show abstract

Treatment of peripheral vascular disease with misoprostol (Cytotec(R)): A pilot study

Cited by 7 publications

References 0 publications

Can misoprostol reduce blood loss in laparoscopy-assisted vaginal hysterectomy?

Can misoprostol reduce blood loss in laparoscopy-assisted vaginal hysterectomy?

Treatment of Chronic Peripheral Arterial Disease

Misoprostol Therapeutics Revisited

Contact Info

Product

Resources

About